PARP1 and cancer: PARP inhibitors are a promising therapeutic strategy in a range of cancer types 7, 8 and have demonstrated the highest activity in cancers of patients with deleterious BRCA mutations associated with homologous recombination pathway deficiency 4, 9, 10.